NASDAQ:ZIOP

ZIOPHARM Oncology Stock Forecast, Price & News

$1.82
+0.13 (+7.69 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.68
$1.85
50-Day Range
$1.44
$2.47
52-Week Range
$1.26
$5.95
Volume5.33 million shs
Average Volume2.65 million shs
Market Capitalization$392.32 million
P/E RatioN/A
Dividend YieldN/A
Beta2.01
30 days | 90 days | 365 days | Advanced Chart
Receive ZIOP News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter.


ZIOPHARM Oncology logo

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.10 out of 5 stars

Medical Sector

447th out of 1,349 stocks

Pharmaceutical Preparations Industry

219th out of 663 stocks

Analyst Opinion: 3.1Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions

Is ZIOPHARM Oncology a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZIOPHARM Oncology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZIOP, but not buy additional shares or sell existing shares.
View analyst ratings for ZIOPHARM Oncology
or view top-rated stocks.

What stocks does MarketBeat like better than ZIOPHARM Oncology?

Wall Street analysts have given ZIOPHARM Oncology a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ZIOPHARM Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ZIOPHARM Oncology's next earnings date?

ZIOPHARM Oncology is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for ZIOPHARM Oncology
.

How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) released its quarterly earnings results on Friday, August, 13th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03.
View ZIOPHARM Oncology's earnings history
.

How has ZIOPHARM Oncology's stock price been impacted by Coronavirus (COVID-19)?

ZIOPHARM Oncology's stock was trading at $2.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZIOP stock has decreased by 28.3% and is now trading at $1.82.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ZIOP?

4 brokerages have issued twelve-month price targets for ZIOPHARM Oncology's stock. Their forecasts range from $3.00 to $5.00. On average, they expect ZIOPHARM Oncology's share price to reach $3.83 in the next twelve months. This suggests a possible upside of 110.6% from the stock's current price.
View analysts' price targets for ZIOPHARM Oncology
or view top-rated stocks among Wall Street analysts.

Who are ZIOPHARM Oncology's key executives?

ZIOPHARM Oncology's management team includes the following people:
  • Heidi M. Hagen, Chief Executive Officer & Director
  • Timothy M. Cunningham, Chief Financial Officer
  • Lynn M. Ferrucci, EVP-Human Resources, Administration & IT
  • Raffaele Baffa, Chief Medical Officer
  • Eleanor M. de Groot, General Manager-Cell Therapy & Executive VP

Who are some of ZIOPHARM Oncology's key competitors?

What other stocks do shareholders of ZIOPHARM Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Precigen (PGEN), Gilead Sciences (gild), OPKO Health (OPK), (CELG), Sangamo Therapeutics (SGMO), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Inovio Pharmaceuticals (INO), Arena Pharmaceuticals (ARNA) and Immunomedics (IMMU).

What is ZIOPHARM Oncology's stock symbol?

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

Who are ZIOPHARM Oncology's major shareholders?

ZIOPHARM Oncology's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.61%), Vanguard Group Inc. (7.32%), State Street Corp (5.04%), Miller Value Partners LLC (4.79%), JPMorgan Chase & Co. (2.24%) and Geode Capital Management LLC (1.65%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney, Groot Eleanor De, Heidi Hagen, Jill Buck, Kevin G Lafond, Laurence James Neil Cooper and Robert Hadfield.
View institutional ownership trends for ZIOPHARM Oncology
.

Which major investors are selling ZIOPHARM Oncology stock?

ZIOP stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Miller Value Partners LLC, State Street Corp, JPMorgan Chase & Co., Bank of New York Mellon Corp, Vanguard Group Inc., Rafferty Asset Management LLC, and Northern Trust Corp. Company insiders that have sold ZIOPHARM Oncology company stock in the last year include Groot Eleanor De, Jill Buck, Kevin G Lafond, Laurence James Neil Cooper, and Robert Hadfield.
View insider buying and selling activity for ZIOPHARM Oncology
or view top insider-selling stocks.

Which major investors are buying ZIOPHARM Oncology stock?

ZIOP stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Millennium Management LLC, Nuveen Asset Management LLC, Bank of America Corp DE, Simplex Trading LLC, Parametric Portfolio Associates LLC, Morgan Stanley, and Morgan Stanley.
View insider buying and selling activity for ZIOPHARM Oncology
or or view top insider-buying stocks.

How do I buy shares of ZIOPHARM Oncology?

Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ZIOPHARM Oncology's stock price today?

One share of ZIOP stock can currently be purchased for approximately $1.82.

How much money does ZIOPHARM Oncology make?

ZIOPHARM Oncology has a market capitalization of $392.32 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-79,980,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis.

How many employees does ZIOPHARM Oncology have?

ZIOPHARM Oncology employs 105 workers across the globe.

When was ZIOPHARM Oncology founded?

ZIOPHARM Oncology was founded in 2005.

What is ZIOPHARM Oncology's official website?

The official website for ZIOPHARM Oncology is www.ziopharm.com.

Where are ZIOPHARM Oncology's headquarters?

ZIOPHARM Oncology is headquartered at ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129.

How can I contact ZIOPHARM Oncology?

ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at (617) 259-1970 or via email at [email protected].


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.